NCT04539938: A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have received 2 or more prior anti-HER2-based regimens in the metastatic setting
Exclusions: Patients previously treated with 1) lapatinib or neratinib within 12 months of starting study treatment, 2) tucatinib or any other investigational HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine kinase inhibitor (TKI) (e.g., afatinib) at any time previously, 3) trastuzumab deruxtecan (DS-8201/Enhertu) or another antibody-drug conjugate consisting of an exatecan derivative

Comments are closed.

Up ↑